The Mass Balance Study of LP-168 in Healthy Subjects

Clinical Pharmacology Clinical Trial

Official title:

The Mass Balance Study of [14C]LP-168 in Chinese Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06126861
• Other study ID #: LP-168-CN104
• Status: Completed
• Phase: Phase 1
• Start date: December 25, 2023
• Est. completion date: March 13, 2024

Study information

• Verified date: February 2024
• Source: Guangzhou Lupeng Pharmaceutical Company LTD.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi [14C]LP-168 in healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: March 13, 2024
• Est. primary completion date: February 2, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy male subjects

• Aged 18-45 (including the boundary value);

• Body weight over 50 kg, the body mass index (BMI) is between 19 and 26 kg/m2 (including the boundary value);

• Subjects must sign the informed consent form voluntarily;

• Agree to abide the requirements of the study protocol, willing to communicate with the study doctor.

Exclusion Criteria:

• After a comprehensive physical examination, vital signs, laboratory tests and other examinations are abnormal and have clinical significance;

• Hepatitis B surface antigen or E antigen, hepatitis C virus antibody IgG (Anti-HCV IgG), human immunodeficiency virus antigen/antibody combined test (HIV-Ag/Ab) and Treponema pallidum antibody test positive;

• Subject with clinically significant abnormalities on ophthalmologic examination (slit lamp, intraocular pressure and fundus photography)

• Subject who have used any drug that inhibits or induces hepatic drug metabolizing enzymes or transporters during the screening period and within the previous 28 days;

• Subject who have taken any medication with inhibition gastric acid secretion during the screening period and within the previous 28 days

• Subject who have taken any anti-gastric acid medication during the screening period and within the previous 28 days

• Subject who have used any systemic medication during the screening period and within the previous 14 days

• Subject with a history of any clinically serious illness or disease or condition that, in the opinion of the investigator, may affect the results of the trial

• Subject with any condition that may affect the absorption of the drug

• Subject with history of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms of QT prolongation syndrome or family history of these syndrome.

• Subject with major surgery during the screening period and within the previous 6 months or surgical incisions that have not fully healed

• Subject with allergies, such as a known history of allergy to two or more substances

• Subject with hemorrhoids or perianal disease with regular or ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease

• Subject with habitual constipation or diarrhea

• Subject with alcohol abuse or regular use of alcohol in the 6 months prior to the screening period

• Subject with smoking >5 cigarettes per day before the first 3 months of the screening period

• Subject with drug abuse

• Subject who are subjected to long-term exposure to radioactive conditions

• Subject who have difficulty collecting blood or cannot tolerate venipuncture for blood collection

• Subject with participation in any other clinical trial during the screening period and within the previous 3 months

• Subject who have been vaccinated during the screening period and within the previous 1 month or who are scheduled to be vaccinated during the trial period

• Subject with plans to have children or donate sperm during the trial and within 1 year after completion of the trial

• Subject who had lost or donated up to 400 mL of blood during the screening period and within the previous 3 months, or those who had received a blood transfusion within 1 month;

• Subject with any factors that the investigator believes make participation in this trial inappropriate

Related Conditions & MeSH terms

• Clinical Pharmacology

Intervention

Drug:
• [14C]LP-168
single dose of 150 mg/100 µCi [14C] LP-168, orally suspension at fasted state

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou Lupeng Pharmaceutical Company LTD.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radioactivity concentration of blood and plasma sample	Use liquid scintillation counter to evaluate Radioactivity concentration of each sample	Day 1- Day 8
Primary	Radioactivity concentration of urine and feces sample	Use liquid scintillation counter to evaluate Radioactivity concentration of each sample	Day 1- Day 15
Primary	Number of metabolites and its proportion in plasma, urine and feces.	To study the metabolite profiling	Day 1- Day 15
Secondary	Plasma LP-168/Major Metabolic concentrations	To determine the plasma concentrations of LP-168/Major Metabolic using LC-MS/MS.	Day 1- Day 8
Secondary	Treatment emergent adverse events as assessed by CTCAE 5.0	To evaluate the safety after the study intervention	Day 1- Day 15